omeprazole has been researched along with Myocardial Infarction in 20 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "In this randomized crossover study analyzing patients after acute myocardial infarction, omeprazole coadministration showed a significant pharmacodynamic interaction with clopidogrel, whereas pantoprazole did not." | 9.15 | Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. ( Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG, 2011) |
| "We investigated the effect of omeprazole (OPZ) and lansoprazole (LPZ) on the pathophysiology of myocardial necrosis in rats by inspecting a series of indicators like hemodynamic parameters, biochemical estimations and histopathological changes in the myocardial tissue." | 7.91 | Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats. ( Goyal, SN; Mahajan, UB; Ojha, S; Patil, AS; Patil, CR; Singh, AD, 2019) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 5.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| "Among patients who had MINS, dabigatran 110 mg twice daily lowered the risk of major vascular complications, with no significant increase in major bleeding." | 5.27 | Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. ( Bangdiwala, SI; Berwanger, O; Biccard, BM; Botto, F; Chaudhry, NK; Connolly, SJ; de Nadal, M; Devereaux, PJ; Duceppe, E; Eikelboom, JW; Erb, J; Franzosi, MG; Guyatt, G; Hoeft, A; Iglesias, PP; Kearon, C; Magloire, P; Mayosi, B; Meyhoff, CS; Neary, J; Pettit, S; Rahate, PV; Rao, M; Rao-Melacini, P; Rodseth, R; Sessler, DI; Sharma, M; Srinathan, SK; Szczeklik, W; Tandon, V; Villar, JC; Vincent, J; Xavier, D; Yusuf, S, 2018) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "In this randomized crossover study analyzing patients after acute myocardial infarction, omeprazole coadministration showed a significant pharmacodynamic interaction with clopidogrel, whereas pantoprazole did not." | 5.15 | Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. ( Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG, 2011) |
| "We investigated the effect of omeprazole (OPZ) and lansoprazole (LPZ) on the pathophysiology of myocardial necrosis in rats by inspecting a series of indicators like hemodynamic parameters, biochemical estimations and histopathological changes in the myocardial tissue." | 3.91 | Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats. ( Goyal, SN; Mahajan, UB; Ojha, S; Patil, AS; Patil, CR; Singh, AD, 2019) |
| " The first compares primary coronary angioplasty with streptokinase in the treatment of acute myocardial infarction, in the second trial, lansoprazole is compared with omeprazole in the treatment of reflux oesophagitis." | 3.70 | Sample size calculation in economic evaluations. ( Al, MJ; Michel, BC; Rutten, FF; van Hout, BA, 1998) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 1.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muthiah, MD | 1 |
| Zheng, H | 1 |
| Chew, NWS | 1 |
| Xiao, J | 1 |
| Lim, LG | 1 |
| Tan, HC | 1 |
| Lee, CH | 1 |
| Low, AF | 1 |
| Foo, LL | 1 |
| Richards, AM | 1 |
| Dan, YY | 1 |
| Ho, KY | 1 |
| Yip, JWL | 1 |
| Chan, MY | 1 |
| Duceppe, E | 2 |
| Yusuf, S | 2 |
| Tandon, V | 2 |
| Rodseth, R | 2 |
| Biccard, BM | 2 |
| Xavier, D | 2 |
| Szczeklik, W | 2 |
| Meyhoff, CS | 2 |
| Franzosi, MG | 2 |
| Vincent, J | 2 |
| Srinathan, SK | 2 |
| Parlow, J | 1 |
| Magloire, P | 2 |
| Neary, J | 2 |
| Rao, M | 2 |
| Chaudhry, NK | 2 |
| Mayosi, B | 2 |
| de Nadal, M | 2 |
| Popova, E | 1 |
| Villar, JC | 2 |
| Botto, F | 2 |
| Berwanger, O | 2 |
| Guyatt, G | 2 |
| Eikelboom, JW | 2 |
| Sessler, DI | 2 |
| Kearon, C | 2 |
| Pettit, S | 2 |
| Connolly, SJ | 2 |
| Sharma, M | 2 |
| Bangdiwala, SI | 2 |
| Devereaux, PJ | 2 |
| Erb, J | 1 |
| Rahate, PV | 1 |
| Iglesias, PP | 1 |
| Rao-Melacini, P | 1 |
| Hoeft, A | 1 |
| Patil, AS | 1 |
| Singh, AD | 1 |
| Mahajan, UB | 1 |
| Patil, CR | 1 |
| Ojha, S | 1 |
| Goyal, SN | 1 |
| Kanth, R | 1 |
| Shah, MS | 1 |
| Flores, RM | 1 |
| Vaduganathan, M | 1 |
| Bhatt, DL | 1 |
| Cryer, BL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Cannon, CP | 1 |
| Gao, QP | 1 |
| Sun, Y | 1 |
| Sun, YX | 1 |
| Wang, LF | 1 |
| Fu, L | 1 |
| Friesen, MH | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Zairis, MN | 1 |
| Tsiaousis, GZ | 1 |
| Patsourakos, NG | 1 |
| Georgilas, AT | 1 |
| Kontos, CF | 1 |
| Adamopoulou, EN | 1 |
| Vogiatzidis, K | 1 |
| Argyrakis, SK | 1 |
| Fakiolas, CN | 1 |
| Foussas, SG | 1 |
| Tran, M | 1 |
| Tafreshi, J | 1 |
| Pai, RG | 1 |
| Fontes-Carvalho, R | 1 |
| Albuquerque, A | 1 |
| Araújo, C | 1 |
| Pimentel-Nunes, P | 1 |
| Ribeiro, VG | 1 |
| Yano, H | 1 |
| Tsukahara, K | 1 |
| Morita, S | 1 |
| Endo, T | 1 |
| Sugano, T | 1 |
| Hibi, K | 1 |
| Himeno, H | 1 |
| Fukui, K | 1 |
| Umemura, S | 1 |
| Kimura, K | 1 |
| Simpson, SE | 1 |
| Mahabaleshwarkar, RK | 1 |
| Yang, Y | 1 |
| Datar, MV | 1 |
| Bentley, JP | 1 |
| Strum, MW | 1 |
| Banahan, BF | 1 |
| Null, KD | 1 |
| Yang, YX | 1 |
| Lewis, JD | 1 |
| Gilard, M | 1 |
| Arnaud, B | 1 |
| Cornily, JC | 1 |
| Le Gal, G | 1 |
| Lacut, K | 1 |
| Le Calvez, G | 1 |
| Mansourati, J | 1 |
| Mottier, D | 1 |
| Abgrall, JF | 1 |
| Boschat, J | 1 |
| Al, MJ | 1 |
| van Hout, BA | 1 |
| Michel, BC | 1 |
| Rutten, FF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery[NCT01661101] | Phase 3 | 1,754 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Epidemiological Patterns, Management Strategies and Cost Analysis of Care for the Patient With Perioperative Myocardial Injury When BNP is Used as a Screening Tool for Non-Cardiac Surgery[NCT04077294] | 333 participants (Actual) | Observational | 2019-05-21 | Completed | |||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo[NCT00349661] | Phase 3 | 120 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
4 reviews available for omeprazole and Myocardial Infarction
| Article | Year |
|---|---|
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients.
Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Ethnicity; Humans; Myocardia | 2021 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Cytoc | 2010 |
Prevention and treatment of stress ulcers in critically ill patients.
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Critical Illness; Female; Gastric Mucosa; Gastrointestinal Hemo | 2003 |
7 trials available for omeprazole and Myocardial Infarction
| Article | Year |
|---|---|
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE).
Topics: Aged; Cause of Death; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Humans; Internatio | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Inf | 2018 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Early use of omeprazole benefits patients with acute myocardial infarction.
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Incidenc | 2009 |
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Dru | 2011 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Dru | 2008 |
9 other studies available for omeprazole and Myocardial Infarction
| Article | Year |
|---|---|
Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats.
Topics: Animals; Electrocardiography; Lansoprazole; Male; Malondialdehyde; Myocardial Infarction; Myocardium | 2019 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids | 2013 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug | 2009 |
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; | 2010 |
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Atti | 2010 |
I've taken aspirin for years to prevent heart attack, and now I've developed an ulcer. My doctor told me to keep taking aspirin along with Prilosec. Why keep taking aspirin if it caused my ulcer?
Topics: Anti-Ulcer Agents; Aspirin; Humans; Myocardial Infarction; Omeprazole; Peptic Ulcer; Platelet Aggreg | 2012 |
A positive event dependence model for self-controlled case series with applications in postmarketing surveillance.
Topics: Computer Simulation; Esomeprazole; Humans; Lactones; Models, Statistical; Myocardial Infarction; Ome | 2013 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; | 2013 |
Sample size calculation in economic evaluations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Cost-Ben | 1998 |